| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 上海之江生物科技股份有限公司（股票代码：688317）成立于2005年，是一家专业从事生物医药分子诊断试剂和仪器设备的研发、生产和销售的高新技术企业，且在最近四次全球突发公共卫生事件（埃博拉、寨卡、新冠、猴痘）中是唯一一家四次均获得WHO认证并列入其官方采购名录的企业。 公司研发的快速实时荧光PCR诊断检测试剂主要应用于医学临床、公共卫生突发事件、出入境检验检疫、食品检验、畜牧业、水产业等领域。公司的十万级和万级生产车间均已通过ISO13485体系论证和国家SFDA体外诊断试剂质量管理考核。目前公司现有500余项的检测与诊断产品，已取得110余项国内医疗器械注册证/备案凭证，其中第三类注册证39项，另外有近300个产品获得欧盟CE认证。公司和子公司现已获得专利70余项，其中发明专利30项。 此外，为更好地服务客户操作便利性、安全性、人员短缺的迫切需求，公司推出了EX系列自动核酸提取仪、Autra系列全自动样本前处理系统、AutraMicmini系列全自动核酸检测一体机以及青耕系列全自动分子检测流水线等11系列30余款仪器设备，持续的自主创新能力和丰富的成果积累为公司快速增长奠定了坚实基础。 公司在仪器设备自动化的研发领域近年来有着极大的创新和突破，目前正也致力于创新技术与上游关键原材料的研发创新。之江生物秉持“质量第一，服务第一”的理念，将全心全意为临床和科研用户提供优质的产品及一站式技术服务。 | ||||||||||||||||||||||||
| Main Business | 分子诊断试剂和仪器设备的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 邵俊斌 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 倪卫琴 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 中汇会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-34635507 | ||||||||||||||||||||||||
| Fax No | 021-34635507 | ||||||||||||||||||||||||
| Website | www.liferiver.com.cn | ||||||||||||||||||||||||
| info@liferiver.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 18/01/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.710 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 19.645 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.661B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |